These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 23846854)

  • 21. Pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases.
    Navarro-Mora G; Alberti JJ; Mondou E; Vilardell D; Vicente Torres J; Ayguasanosa J; Páez A
    Int Immunopharmacol; 2022 Mar; 104():108472. PubMed ID: 35008008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Experience of Subcutaneous Immunoglobulin Therapy in Pediatric Primary Immunodeficient Patients with Low and Normal Body Weight.
    Gul Y; Kapakli H; Guner SN; Alan HB; Hazar E; Keles S; Reisli I
    J Clin Immunol; 2022 Jan; 42(1):64-71. PubMed ID: 34617265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction.
    Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I
    Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis.
    Shapiro R
    J Clin Immunol; 2010 Mar; 30(2):301-7. PubMed ID: 20082124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency.
    Hoffmann F; Grimbacher B; Thiel J; Peter HH; Belohradsky BH;
    Eur J Med Res; 2010 Jun; 15(6):238-45. PubMed ID: 20696632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency.
    Visentin A; Molinari MC; Pravato S; Cellini A; Angotzi F; Cavaretta CA; Ruocco V; Imbergamo S; Piazza F; Proietti G; Mauro FR; Trentin L
    Curr Oncol; 2022 Dec; 30(1):274-283. PubMed ID: 36661671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.
    Berger M; Rojavin M; Kiessling P; Zenker O
    Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
    Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
    Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies.
    Soler-Palacín P; Gasó-Gago I; Fernández-Polo A; Martín-Nalda A; Oliveras M; Martinez-Cutillas J; Figueras C
    J Clin Immunol; 2014 Nov; 34(8):1015-7. PubMed ID: 25190197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies.
    Pecoraro A; Ricci S; Vultaggio A; Boggia GM; Spadaro G;
    Clin Drug Investig; 2020 Mar; 40(3):279-286. PubMed ID: 32036588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy.
    Orange JS; Belohradsky BH; Berger M; Borte M; Hagan J; Jolles S; Wasserman RL; Baggish JS; Saunders R; Grimbacher B
    Clin Exp Immunol; 2012 Aug; 169(2):172-81. PubMed ID: 22774992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.
    Shapiro RS
    Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder.
    Sarı G; Güven Bilgin B; Yılmaz E; Aytac G; Edeer Karaca N; Aksu G; Kutukculer N
    Eur Ann Allergy Clin Immunol; 2021 Jul; 53(4):177-184. PubMed ID: 33191716
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy and Tolerability of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Neurologic Diseases.
    Chen Y; Wang C; Xu F; Ming F; Zhang H
    Clin Ther; 2019 Oct; 41(10):2112-2136. PubMed ID: 31445679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study.
    Vultaggio A; Azzari C; Milito C; Finocchi A; Toppino C; Spadaro G; Trizzino A; Baldassarre M; Paganelli R; Moschese V; Soresina A; Matucci A
    Clin Drug Investig; 2015 Mar; 35(3):179-85. PubMed ID: 25672929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.
    Jolles S; Rojavin MA; Lawo JP; Nelson R; Wasserman RL; Borte M; Tortorici MA; Imai K; Kanegane H
    J Clin Immunol; 2018 Nov; 38(8):864-875. PubMed ID: 30415311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
    Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
    Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunoglobulin replacement treatment by rapid subcutaneous infusion.
    Gaspar J; Gerritsen B; Jones A
    Arch Dis Child; 1998 Jul; 79(1):48-51. PubMed ID: 9771252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID).
    Viallard JF; Brion JP; Malphettes M; Durieu I; Gardembas M; Schleinitz N; Hoarau C; Lazaro E; Puget S
    Rev Med Interne; 2017 Sep; 38(9):578-584. PubMed ID: 28683953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin.
    Li Z; McCoy B; Engl W; Yel L
    J Clin Immunol; 2021 Aug; 41(6):1331-1338. PubMed ID: 34036490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.